<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cyproterone (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cyproterone (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cyproterone (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11709" href="/d/html/11709.html" rel="external">see "Cyproterone (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866476"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Androcur;</li>
<li>Androcur Depot;</li>
<li>MED-Cyproterone;</li>
<li>RIVA-Cyproterone</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F155804"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiandrogen;</li>
<li>
                        Antineoplastic Agent, Antiandrogen</li></ul></div>
<div class="block doa drugH1Div" id="F155794"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f7c50b11-ac37-4128-a6d9-8bbf225e4781">Hormone therapy for transgender females</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hormone therapy for transgender females (assigned male at birth) (adjunct) (off-label use): Oral: </b>25 to 50 mg/day in combination with other appropriate agents; adjust dose with a goal of suppressing serum testosterone levels into the normal range for females (ie, &lt;50 ng/dL) (ES [Hembree 2017]). Dosage range: 12.5 to 50 mg/day, the lowest effective dose is recommended (Angus 2019; Burinkul 2021; Cheung 2019; Even Zohar 2021; Tangpricha 2017; T'Sjoen 2020).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b254bcd-114d-4125-9ef3-2cbe93742442">Paraphilia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Paraphilia (off-label use): </b> Males (<b>Note:</b> Avoid use if active pituitary pathology, hepatic failure, or thromboembolic disease):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Usual dose range: 50 to 200 mg/day; maximum dose: 600 mg/day (Guay 2009; Reilly 2000).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 300 to 600 mg every 1 to 2 weeks (Guay 2009) <b>or</b> 400 to 700 mg once a week (Reilly 2000).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88110d5f-4659-4a15-88dc-c532d395d217">Prostate cancer, advanced, palliative treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, advanced, palliative treatment:</b>
<b>Note:</b> May interchange between oral and IM administration during chronic therapy; dosages should remain within usual ranges (oral: 100 to 300 mg daily; IM: 300 mg weekly or every 2 weeks).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 200 to 300 mg daily in 2 to 3 divided doses (maximum: 300 mg daily); following orchiectomy, reduce dose to 100 to 200 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 300 mg once weekly; reduce dose in orchiectomized patients to 300 mg once every 2 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990262"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); use with caution</p></div>
<div class="block doha drugH1Div" id="F50987435"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated with hepatic impairment or liver disease. Discontinue if hepatotoxicity develops during treatment.</p></div>
<div class="block dot drugH1Div" id="F56492892"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Meningioma: Permanently discontinue cyproterone.</p>
<p style="text-indent:-2em;margin-left:2em;">Prostate specific antigen progression: Discontinue cyproterone immediately; monitor for 6 to 8 weeks for withdrawal response.</p>
<p style="text-indent:-2em;margin-left:2em;">Thrombophlebitis/thromboembolism: Discontinue cyproterone.</p></div>
<div class="block doe drugH1Div" id="F3062977"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F155769"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, cardiac failure, cerebrovascular accident, edema, hypotension, phlebitis, pulmonary embolism (including oil microembolism), retinal thrombosis, retinal vascular disease, shock, syncope, tachycardia, thrombosis (deep vein thrombosis, embolism, superficial venous thrombosis), vasodepressor syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, eczema, erythema nodosum, exfoliative dermatitis, loss of body hair (patchy), maculopapular rash, pruritus, skin discoloration, skin photosensitivity, skin rash, urticaria, xeroderma (sebum reduction)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenal suppression (dose-related), decreased cortisol, decreased libido, diabetes mellitus, galactorrhea not associated with childbirth, gynecomastia, hirsutism, hot flash, hypercalcemia, hyperglycemia, hypernatremia, negative nitrogen balance, secondary adrenocortical insufficiency, weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, constipation, diarrhea, dyspepsia, glossitis, nausea, pancreatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Benign breast nodule, breast hypertrophy, breast tenderness, crystalluria, hematuria, impotence, inhibition of spermatogenesis, urinary frequency, uterine hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, bladder carcinoma, decreased prothrombin time, hemolytic anemia, hemorrhage, hepatic carcinoma, hypochromic anemia, increased serum fibrinogen, leukocytosis, leukopenia, normocytic anemia, thrombocytopenia, uterine fibroid enlargement</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites, cholestatic jaundice, hepatic cirrhosis, hepatic coma, hepatic failure, hepatic insufficiency (dose-related), hepatic necrosis, hepatic neoplasm, hepatitis, hepatomegaly, increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait, aphasia, chills, coma, depression, dizziness, encephalopathy, fatigue, headache, hemiplegia, lassitude, malaise, myasthenia, personality disorder, psychotic depression, restlessness, vascular headache</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular and skeletal: Asthenia, osteoporosis, systemic sclerosis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance, blindness, optic atrophy, optic neuritis, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine, renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, cough, dyspnea, dyspnea on exertion, hyperventilation, pulmonary fibrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hematologic &amp; oncologic: Meningioma (rare: &lt;1%; with increasing cumulative doses) (EMA 2020)</p></div>
<div class="block coi drugH1Div" id="F155781"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to cyproterone or any component of the formulation; liver disease or hepatic dysfunction; Dubin-Johnson syndrome; Rotor syndrome; previous or existing liver tumors (if not due to metastases from prostate cancer); presence or history of meningioma; wasting diseases (except inoperable prostate cancer); severe chronic depression; existing thromboembolic processes</p></div>
<div class="block war drugH1Div" id="F155767"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenalcortical function suppression: Suppression of the adrenal gland and adrenal function tests have been reported with cyproterone.</p>
<p style="text-indent:-2em;margin-left:4em;">• Anemia: Hypochromic anemia has been observed (rarely).</p>
<p style="text-indent:-2em;margin-left:4em;">• Antiandrogen withdrawal syndrome: Antiandrogens may promote prostate cancer growth in some patients with metastatic prostate cancer; may present as prostate-specific antigen (PSA) progression. Decreased PSA levels and/or clinical improvement have been reported following therapy discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Carcinogenesis: Benign and malignant hepatic tumors have been observed (rarely) after use; rule out the presence of tumor in patients presenting with severe upper abdominal discomfort, hepatic enlargement or signs of intra-abdominal hemorrhage. Meningioma formation has been reported with chronic therapy (years) at doses ≥25 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: Lassitude, weakness, and fatigue are common during first few weeks of treatment; symptoms usually lessen from the third month after initiation. Patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic effects: Dry skin and/or transient alopecia may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gynecomastia: Benign hyperplasia of the breast has been reported; subsides usually within 1 to 3 months after therapy discontinuation and/or dose reduction. Risk of treatment failure should be considered prior to discontinuation or dose reduction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity:<b> [Canadian Boxed Warning]: Cyproterone is associated with hepatotoxicity. Dose-dependent hepatotoxicity (jaundice, hepatitis, acute hepatic failure) has been observed, including fatal case reports with doses ≥100 mg/day.</b> Most reported fatalities were in males treated for prostate cancer. Hepatotoxicity typically develops a few weeks to several months after treatment initiation. Use caution with concurrent use of other hepatotoxic drugs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Metabolic effects: Changes in lipid profile, hypercalcemia, and/or fluid retention may occur; a negative nitrogen balance is usual at therapy initiation but typically corrects itself within 3 months of ongoing therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory effects: Shortness of breath was commonly observed in patients receiving cyproterone doses of 300 mg/day; patients with existing pulmonary dysfunction may be more susceptible to respiratory effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolism: Cyproterone may increase the risk of thromboembolism (particularly when used in combination with ethinyl estradiol). Use with caution in patients with an inoperable prostate tumor, history of thromboembolic processes, sickle cell anemia or severe diabetes with vascular changes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Carefully observe patients with a tendency toward depression; cyproterone has been associated with an increased incidence of depressive mood changes, particularly early in the course of therapy (initial 6 to 8 weeks).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Cyproterone may impair carbohydrate metabolism. Patients with diabetes may require adjustments in diabetes medications during cyproterone treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Solution is oil based and must be injected by slow intramuscular injection only; avoid intravascular injection. Pulmonary microembolism of oily solutions can occur and lead to cough, dyspnea, angina and vasovagal reactions (eg, syncope, malaise, dizziness, hyperhidrosis, paresthesia). Reactions can occur during or immediately after the injection and are reversible; may usually be managed with supportive care (eg, oxygen).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ethanol consumption: Although the relevance to the treatment of prostate cancer is unknown, the antiandrogen effects in hypersexuality may be reduced with ethanol. Ethanol should be avoided during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Combination therapy: Retrospective meta-analysis data suggest that 5-year survival rates may be lower when used concomitantly with a GnRH agonist or orchiectomy versus patients treated with castration alone.</p></div>
<div class="block prod-avail drugH1Div" id="F11218428"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F53040720"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52866477"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Oil, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Androcur Depot: 100 mg/mL (3 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Androcur: 50 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg</p></div>
<div class="block adm drugH1Div" id="F155778"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Administer IM injections slowly and avoid intravascular injection, which can lead to pulmonary microembolism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer tablets at the same time each day, after meals and with liquids.</p></div>
<div class="block hazard drugH1Div" id="F49130958"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Cyproterone may cause carcinogenicity, teratogenicity, reproductive toxicity, genotoxicity, and has a structural or toxicity profile similar to existing hazardous agents.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F155777"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, advanced:</b> Palliative treatment of advanced prostate cancer.</p></div>
<div class="block off-label drugH1Div" id="F25722049"><span class="drugH1">Use: Off-Label: Adult</span><p>Hormone therapy for transgender females (assigned male at birth); Paraphilia</p></div>
<div class="block mst drugH1Div" id="F26116832"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299112"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F6219608"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May diminish the therapeutic effect of Cyproterone. More specifically, alcohol may interfere with antiandrogenic effects of Cyproterone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Progestins may enhance the adverse/toxic effect of Chlorprothixene. Progestins may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Choline C 11: Antiandrogens may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Cyproterone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Cyproterone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flotufolastat F18: Antiandrogens may diminish the diagnostic effect of Flotufolastat F18.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of flotufolastat F18 in prostate cancer. The impact of these therapies on the performance of flotufolastat F18 is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 PSMA-11: Antiandrogens may diminish the therapeutic effect of Gallium Ga 68 PSMA-11.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of gallium Ga 68 PSMA-11 (gozetotide) in prostate cancer. The impact on the performance of gallium Ga 68 PSMA-11 (gozetotide) is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HMG-CoA Reductase Inhibitors (Statins): Cyproterone may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Progestins may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking progestins.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piflufolastat F18: Antiandrogens may diminish the diagnostic effect of Piflufolastat F18.  Management: Therapies targeting the androgen pathway may result in changes in the uptake of piflufolastat F18 in prostate cancer. The impact of these therapies on the performance of piflufolastat F18 is unknown; consider use of alternative agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Cyproterone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: May diminish the therapeutic effect of Progestins. Progestins may diminish the therapeutic effect of Ulipristal.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F155790"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Ethanol may reduce the effect of cyproterone (not established in the treatment of prostatic carcinoma). Management: Avoid concurrent use.</p></div>
<div class="block rep_considerations drugH1Div" id="F49296869"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">When used for the treatment of advanced prostate cancer, sperm count and volume of ejaculate will be reduced at oral doses of 50 to 300 mg/day. After ~2 months of treatment, infertility may be noted. Changes are reversible upon discontinuation of therapy, usually within 3 to 5 months although in some patients may take up to 20 months. Production of abnormal spermatozoa has been observed although the effect on fertilization or embryo formation is unknown.</p>
<p style="text-indent:0em;">Cyproterone is used off-label in combination with estrogen to block androgens in transgender females. Complete suppression of spermatogenesis may not occur; therefore, contraception is recommended to prevent unintended pregnancies. Patients should consider options for fertility preservation prior to gender-affirming hormone therapy (Vereecke 2021).</p></div>
<div class="block pri drugH1Div" id="F155782"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Not indicated for use in patients who can become pregnant.</p></div>
<div class="block brc drugH1Div" id="F21099229"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Cyproterone is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">A single oral dose of cyproterone 50 mg was administered to 6 women 8 days postpartum. Cyproterone concentrations 3 hours after the maternal dose were 65 to 449 ng/mL (plasma) and 16 to 260 ng/mL (breast milk). Nine hours after the maternal dose, cyproterone concentrations were 76 to 267 ng/mL (plasma) and 55 to 130 ng/mL (breast milk) (Stoppelli 1980).</p></div>
<div class="block mop drugH1Div" id="F155773"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">LFTs (at baseline and periodically thereafter, or as clinically indicated with signs or symptoms suggestive of hepatotoxicity), CBC (regularly), adrenal function tests (via serum cortical assay [periodically]), electrolytes (regularly), fasting blood glucose and glucose tolerance (at baseline and regularly during treatment in patients with diabetes). In patients with prostate-specific antigen (PSA) progression, monitor for withdrawal response syndrome (eg, decrease in PSA levels) for 6 to 8 weeks following cyproterone discontinuation. Monitor for signs/symptoms of depression.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Transgender hormone therapy</b>: Serum testosterone levels (goal: &lt;50 ng/dL) every 3 months during the first year and then annually or biannually; routine cancer and laboratory screening as in non-transgender individuals for all tissues present (ES [Hembree 2017]).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Paraphilia</b> (Guay 2009; Reilly, 2000): ECG; hepatic function test (baseline and during treatment if suspected hepatotoxicity); CBC (baseline); serum testosterone (baseline then monthly for 4 months then every 6 months); serum luteinizing hormone and prolactin (baseline and every 6 months); follicle-stimulating hormone (baseline); glucose; bone scan (baseline then annually) if serum testosterone significantly suppressed; blood pressure; weight gain.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<b>Cardiovascular monitoring for patients with prostate cancer:</b> Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking; baseline and serial ECGs are recommended in patients at risk of QTc prolongation during androgen deprivation therapy (ADT); estimate 10-year cardiovascular disease risk in patients without cardiovascular disease at baseline; assess cardiovascular risk annually during ADT (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F155766"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Cyproterone is a steroid with antiandrogenic, antigonadotropic, and progestin-like activity. Blocks binding of dihydrotestosterone (DHT) to prostatic cancer cells and exerts negative feedback on hypothalamic-pituitary axis by inhibiting luteinizing hormone (LH) secretion leading to decreased testosterone production.</p></div>
<div class="block phk drugH1Div" id="F155780"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: Complete </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 96% (Guay 2009)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic; primary metabolite is 15beta-hydroxy-cyproterone acetate </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: IM: 20.6 L/kg (Guay 2009)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Oral: 88% (Guay 2009)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Oral: 38 ± 5 hours; Depot injection: 4 days</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: Oral: 3 to 4 hours; Depot injection: 3.4 days </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (60%); urine (33%; mainly as unconjugated metabolites)</p></div>
<div class="block phksp drugH1Div" id="F51220875"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Elderly: Oral: Clearance decreased 25%, volume of distribution increased 55%, and half-life increased 2-fold (Guay 2009).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F155783"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Asoteron | C.p.d. | Ceprater | Ciclamil | Ciprofarma | Cipronova | Ciproplex | Ciproterona | Ciproterona deltafarma | Ciproterona gp pharm | Ciproterona Kilab | Ciproterona microsules | Ciproterona rontag | Ciproterona Servycal | Hitoron | Kebirterona</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Andro-diane | Androcur</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Anterone | Apo-cyproterone | Cyprocur | Cyprohexal | Cyprone | Cyprostat | Cyproterone | Cyproterone an | Cyproterone pharmacor | Cyproterone ps | Cyproterone sandoz | Cyrotone | Procur</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Cyproplex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Cyproterone Acetat</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acetato de Ciproterona | Andelux | Androcur | Androsteron | Cetoteron | Ciprostat | Prostman</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Androbas | Androcur</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Ciproviron</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Sai pu long</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Ciproterona | Ciproterona acetato | Cyproplex | Olter | Oncoterona</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Cyproplex | Cysaxal</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Cyproteron TAD | Cyproteronacetat beta | Cyproteronacetat-gry | Virilit</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Ciproterona Sandoz | Zendar</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Androstat | Ciproterona Acetate</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Imvel</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Acetate de cyproterone Arrow | Acetate de Cyproterone EG | Androcur | Cyproterone biogaran | Cyproterone merck | Cyproterone winthrop | Erapyl | Kaliale</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Cyprostat | Cyproterone | Cyproterone Almus | Cyproterone cox | Cyproterone kent | Cyproterone sandoz</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Apo-cyproterone</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Cysaxal</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Armocur | Cypron</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Androcul | Androcur</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Androcure</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Cyproplex</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Cyproplex | Imvel</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Cypron</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Cyproteronacetaat | Cyproteronacetaat Merck</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Pacif cyproterone | Procur | Siterone</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Ciproterona | Neoteron</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Androstat</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Ciproterona</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Androstat | Ceprater | Ciproterona acetato</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Androcur depot | Cyproterone teva</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Apo-cyproterone</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Cyproteron Mylan | Cyproteronacetat ebb</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Cyproplex | Cysaxal</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Androcur</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Cyrona | Synteron</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Androcur depot</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Ceprater | Ciclamida | Ciproterona delta farma | Ciproterona Servycal | Prostaden</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Asoteron | Ciproterona</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Androcur | Cipla-cyproterone | Cyproplex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF-38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference">
                  Androcur and Androcur Depot (cyproterone) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31234145">
<a name="31234145"></a>Angus L, Leemaqz S, Ooi O, et al. Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy. <i>Endocr Connect</i>. 2019;8(7):935-940. doi:10.1530/EC-19-0272<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/31234145/pubmed" id="31234145" target="_blank">31234145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol.</i> 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34274044">
<a name="34274044"></a>Burinkul S, Panyakhamlerd K, Suwan A, Tuntiviriyapun P, Wainipitapong S. Anti-androgenic effects comparison between cyproterone acetate and spironolactone in transgender women: a randomized controlled trial.<i> J Sex Med</i>. 2021;18(7):1299-1307. doi:10.1016/j.jsxm.2021.05.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/34274044/pubmed" id="34274044" target="_blank">34274044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31271465">
<a name="31271465"></a>Cheung AS, Wynne K, Erasmus J, Murray S, Zajac JD. Position statement on the hormonal management of adult transgender and gender diverse individuals. <i>Med J Aust</i>. 2019;211(3):127-133. doi:10.5694/mja2.50259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/31271465/pubmed" id="31271465" target="_blank">31271465</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  European Medicines Agency (EMA). Restrictions in use of cyproterone due to meningioma risk. https://www.ema.europa.eu/en/news/restrictions-use-cyproterone-due-meningioma-risk-0. Published 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34176757">
<a name="34176757"></a>Even Zohar N, Sofer Y, Yaish I, Serebro M, Tordjman K, Greenman Y. Low-dose cyproterone acetate treatment for transgender women. <i>J Sex Med</i>. 2021;18(7):1292-1298. doi:10.1016/j.jsxm.2021.04.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/34176757/pubmed" id="34176757" target="_blank">34176757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21504253">
<a name="21504253"></a>Garcia FD, Thibaut F. Current concepts in the pharmacotherapy of paraphilias. <i>Drugs</i>. 2011;71(6):771-790.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/21504253/pubmed" id="21504253" target="_blank">21504253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19243704">
<a name="19243704"></a>Guay DR. Drug Treatment of Paraphilic and Nonparaphilic Sexual Disorders. <i>Clin Ther</i>. 2009;31(1):1-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/19243704/pubmed" id="19243704" target="_blank">19243704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29320642">
<a name="29320642"></a>Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. <i>Endocr Pract</i>. 2017;23(12):1437. doi:10.4158/1934-2403-23.12.1437<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/29320642/pubmed" id="29320642" target="_blank">29320642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10986575">
<a name="10986575"></a>Reilly DR, Delva NJ, Hudson RW. Protocols for the Use of Cyproterone, Medroxyprogesterone, and Leuprolide in the Treatment of Paraphilia. <i>Can J Psychiatry</i>. 2000;45(6):559-563.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/10986575/pubmed" id="10986575" target="_blank">10986575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7193550">
<a name="7193550"></a>Stoppelli I, Rainer E, Hümpel M. Transfer of cyproterone acetate to the milk of lactating women. <i>Contraception</i>. 1980;22(5):485-493. doi:10.1016/0010-7824(80)90101-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/7193550/pubmed" id="7193550" target="_blank">7193550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27916515">
<a name="27916515"></a>Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. <i>Lancet Diabetes Endocrinol</i>. 2017;5(4):291-300. doi:10.1016/S2213-8587(16)30319-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/27916515/pubmed" id="27916515" target="_blank">27916515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32452729">
<a name="32452729"></a>Thibaut F, Cosyns P, Fedoroff JP, et al; WFSBP Task Force on Paraphilias. The World Federation of Societies of Biological Psychiatry (WFSBP) 2020 guidelines for the pharmacological treatment of paraphilic disorders. <i>World J Biol Psychiatry</i>. 2020;21(6):412-490. doi:10.1080/15622975.2020.1744723<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/32452729/pubmed" id="32452729" target="_blank">32452729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32111534">
<a name="32111534"></a>T'Sjoen G, Arcelus J, De Vries ALC, et al. European Society for Sexual Medicine position statement "Assessment and Hormonal Management in Adolescent and Adult Trans People, With Attention for Sexual Function and Satisfaction". <i>J Sex Med</i>. 2020;17(4):570-584. doi:10.1016/j.jsxm.2020.01.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/32111534/pubmed" id="32111534" target="_blank">32111534</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33257947">
<a name="33257947"></a>Vereecke G, Defreyne J, Van Saen D, et al. Characterisation of testicular function and spermatogenesis in transgender women. <i>Hum Reprod</i>. 2021;36(1):5-15. doi:10.1093/humrep/deaa254<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/33257947/pubmed" id="33257947" target="_blank">33257947</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9295 Version 221.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
